A Phase II Study of Bevacizumab Alone or in Combination with TRC105 for Advanced Renal Cell Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Bevacizumab (Primary) ; Carotuximab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 17 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
- 05 Dec 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Mar 2017.